Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02557971

Enrollment

315

Registered

2015-09-23

Start date

2015-08-31

Completion date

2016-07-31

Last updated

2016-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Bladder, Overactive

Brief summary

This study is a retrospective chart review of patients treated with BOTOX® for idiopathic Overactive Bladder (OAB) as standard of care in clinical practice. The study will determine the rate of post procedural urinary retention requiring catheterization and identify factors that may predict urinary retention.

Interventions

DRUGonabotulinumtoxinA

OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

-Patients treated with BOTOX® for Overactive Bladder.

Exclusion criteria

* Received botulinum toxin formulations other than BOTOX® in the bladder. * Had symptoms of OAB associated with a neurological condition. * Had a history of chronic urinary retention treated with Clean Intermittent Catheterization (CIC) or indwelling catheter.

Design outcomes

Primary

Measure	Time frame
Percentage of Participants with Post-Procedure Urinary Retention requiring Catheterization	12 Weeks
Length of Time of Clean Intermittent Catheterization (CIC) Use	12 Weeks

Secondary

Measure	Time frame
Percentage of Participants with Urinary Tract Infection (UTI)	12 Weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026